BMC Cardiovascular Disorders · 2023 · 12 citations · 26 references
MedicineCardiologyClinical CardiologyEpidemiologic MethodsInterventional CardiologyAcute Coronary Syndrome InterventionAcute Coronary SyndromesCardiac Risk AssessmentCardiovascular DiseaseCardiovascular RiskIschemic Heart DiseaseHigh-density Lipoprotein Cholesterol MeasurementHigh-risk Non-st Elevation Myocardial InfarctionLong-term Prognosis EstimationNon-st-elevation Myocardial InfarctionPercutaneous Coronary Intervention CarePlasma Cholesterol LevelsRestricted Cubic Spline Models
BACKGROUND: Studies in populations with or without cardiovascular disease have shown that very high HDL-C levels are associated with an increased risk of cardiovascular events. However, the exact relationship between HDL-C levels and long-term prognosis remains unknown in patients with myocardial infarction (MI) undergoing percutaneous coronary intervention (PCI). METHODS: This was a post hoc secondary analysis of long-term follow-up results in patients undergoing PCI open-label, observational cohort study. Patients with MI who had undergone PCI were enrolled. Restricted cubic spline (RCS) analysis and logistic regression analysis were performed to assess the relationship between HDL-C levels and the risk of cardiovascular events. RESULTS: A total of 1934 patients with MI undergoing PCI were enrolled in our analysis and our population was divided in 3 groups according to the HDL-C plasma levels: HDL-C < 40 mg/dL (low HDL-C); HDL-C between 40 and 80 mg/ dL (medium HDL-C); and HDL-C > 80 mg/dL (high HDL-C). RCS analysis showed a nonlinear U-shaped association between HDL-C levels and major adverse cardiac and cerebrovascular events (MACCE) in patients with NSTEMI with adjusted variables. After adjusting for potential confounders, the follow-up analysis indicated that high risk group had elevated occurrence of MACCE than low risk group (HDL-C 35 and 55 mg/dL) (OR:1.645, P = 0.006). CONCLUSIONS: Our analysis demonstrated that there is a U-shaped association between HDL-C and MACCE in patients with NSTEMI undergoing PCI.
26
Effects of Torcetrapib in Patients at High Risk for Coronary Events
Philip J. Barter, Mark J. Caulfield, Mats Eriksson et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text
Medicine, Cardiology, Pharmacology +14
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz, Anders Olsson, Markus Abt et al. · New England Journal of Medicine · 2012 · 2K citations · Full text
Medicine, Cardiology, Pharmacology +17